David Bejker, M.Sc.
Chief Executive Officer
Mr. Bejker has experience from the biotech industry both as an investor and as a business developer. Most recently he worked at HealthCap, a family of multi stage venture capital funds. Bejker has previously worked with business development at Affibody. Mr. Bejker holds a M.Sc. in Business and Economics from the Stockholm School of Economics, where he was awarded the Karl-Adam Bonnier Scholarship to Darden Graduate Business School, Charlotteville, Virginia.
Johan Stuart, M.Sc.
Chief Financial Officer
Mr. Stuart has a M.Sc. in Finance and Business Administration from the Stockholm School of Economics. He has more than 15 years' experience as CFO of listed and unlisted companies, and has been involved in three Initial Public Offerings. Most recently he was CFO of the Swedish life science company XCounter AB, which he helped list on the AIM market of the London Stock Exchange in 2006.
Lars Abrahmsén, Ph.D.
Chief Scientific Officer
Dr. Abrahmsén earned his Ph.D. from the Royal Institute of Technology in Stockholm, where his research focused on protein engineering. He has two years’ post-doctoral research experience at Genentech and 13 years experience in developing small molecule and protein pharmaceuticals with KabiPharmacia, Pharmacia & Upjohn and Biovitrum. Prior to joining Affibody, Dr. Abrahmsén was Senior Project Team Leader at Biovitrum, a position that included responsibility for activities ranging from high throughput screening to in vivo pharmacology.
Karin Nord, Ph.D.
SVP Operations
Dr Nord is one of the co-founders of Affibody and was one of the first employees; she had an important role in the establishment of the company in 1998. Dr Nord received her Ph.D., which included pioneering work on Affibody® molecules, from the Royal Institute of Technology in Stockholm in 1999. Dr. Nord was the lead author of the first report on Affibody® molecules, published in Nature Biotechnology in 1997.